GRI Bio, Inc.
GRI Bio, Inc. (GRI): 2 pipeline candidates · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.1 months
D/E 0.08 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for GRI Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.8M
Cash
$11.0M
Quarterly Burn
$3.7M
Runway
9.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$42K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 18,438 | $42K |
| blackrock, inc. | 7 | $16 |
| danske bank a/s | 2 | $5 |
Frequently asked questions
How many drug candidates are in GRI Bio, Inc.'s pipeline?
GRI Bio, Inc. (GRI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GRI Bio, Inc.'s lead drug candidate?
GRI Bio, Inc.'s most advanced tracked candidate is gri-0621 (Phase 2) for Idiopathic pulmonary fibrosis (IPF).
What is GRI Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GRI Bio, Inc. has approximately 9.1 months of cash runway.
What is GRI Bio, Inc.'s market capitalization?
GRI Bio, Inc.'s market capitalization is approximately $3.8M.
Who is the CEO of GRI Bio, Inc.?
Dr. W. Marc Hertz Ph.D. is the chief executive officer of GRI Bio, Inc. (GRI).
Get the full picture on GRI Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.